FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					SERIAL NO.			10/650,608	
					FILING DATE		28 Aug 2	28 Aug 2003	
					APPLICANT		Jean-Pau	Jean-Paul Cassart et al	
					GROUP		1642	1642	
					EXAMINER		Min-Tan	Min-Tam Davis	
					ATTORNEY DOCKET NO.			BC45300-1US	
U.S. PATENT DOCUMENTS									
								Filing Date	
Examiner Initials				Name	Class	Subclass	If Appropriate		
_									
FOREIGN PATENT DOCUMENTS									
		Document Number	ocument Publication			Class	Subclass	Translation Yes No	
			Date		3041117	CAMOS	Dantanos		
	_								
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)									
	1	Arteaga (2002) "Trastuzumab, an appropriate first-line single-agent therapy for HER2- overexpressing metastitic breast cancer," <i>Breast Cancer Res.</i> 5:96-100.							
	2	Mitchell (2002) "Cancer vaccines, a critical reviewPart II," Curr Opin Investig Drugs. 3:150-8							
	3	Reiter (1998) "Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer," PNAS 95:1735-1740.							
	4	Ross (2002) "Prostate Stem Cell Antigen as Therapy Target: Tissue Expression and in Vivo Efficacy of an Immunoconjugate," Cancer Research 62:2546-2553							
	5	Garcia-Hernandez (2008) "Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in the Absence of Autoimmunity," Cancer Research 68:861-869.							
	6	GlaxoSmithKline Biologicals, No. 001, "Antigen Specific Cancer Immunotherapeutics: Educating the patient's immune defense to fight cancer" (2007).							
EXAMINER						DATE	CONSIDERE	D	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.